Outlook Therapeutics

+$0.03 (+1.17%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell OTLK and other stocks, options, and ETFs commission-free!

About OTLK

Outlook Therapeutics, Inc. Common Stock, also called Outlook Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.

CEO
Lawrence A. Kenyon
Employees
8
Headquarters
Iselin, New Jersey
Founded
2010

OTLK Key Statistics

Market Cap
465.43M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
832.65K
High Today
$2.63
Low Today
$2.54
Open Price
$2.56
Volume
741.46K
52 Week High
$4.26
52 Week Low
$0.58

OTLK Earnings

-$0.62
-$0.40
-$0.17
$0.05
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected Aug 13, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure